Am. J. Respir. Crit. Care Med., Volume 157, Number 4, April 1998, 1319-1323

Reduced E-Cadherin Expression Is Associated with Increased Lymph Node Metastasis and Unfavorable Prognosis in Non-small Cell Lung Cancer

MAARTEN A. SULZER, MATHIE P. G. LEERS, JAN A. van NOORD, EWALD C. M. BOLLEN, and PAUL H. M. H. THEUNISSEN

Departments of Pulmonary Medicine, Pathology, and Surgery, De Wever Hospital, Heerlen, the Netherlands

E-cadherin is a calcium-dependent, epithelial cell adhesion molecule whose reduced expression has been associated with tumor dedifferentiation and increased lymph node metastasis in clinical studies involving several carcinomas. In this study, 111 patients who had previously undergone complete resection and systematic mediastinal lymph node dissection for non-small cell lung cancer (NSCLC) were studied retrospectively. In the primary tumor, as well as in the lymph node metastases, E-cadherin expression was detected by immunohistochemistry using a monoclonal antibody (HECD-1; Takara, Otsu, Japan). There was a significant inverse correlation between E-cadherin expression and lymph node stage (Pearson correlation coefficient 0.52, p = 0.0001) as well as tumor differentiation (Pearson correlation coefficient 0.27, p = 0.005). Moreover, Kaplan and Meier survival estimates showed a significant correlation between E-cadherin expression and patient survival in log rank testing (p = 0.006). In the patient group with the highest proportion of E-cadherin positive tumor cells, 60% of the patients were still estimated to be alive at 36 mo, versus 32% of the patients in the group classified as showing negative E-cadherin expression. Our findings provide clinical evidence that reduced E-cadherin expression is associated with tumor dedifferentiation, increased lymphogenous metastasis and poor survival. It seems therefore that E-cadherin expression might be an important prognostic factor in NSCLC.

This article has been cited by other articles:

				C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]

				Mechanisms and Limits of Induced Postnatal Lung Growth Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 319 - 343. [Full Text] [PDF]

				R. Reddy, S. Buckley, M. Doerken, L. Barsky, K. Weinberg, K. D. Anderson, D. Warburton, and B. Driscoll Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L658 - L667. [Abstract] [Full Text] [PDF]

				T. Ohira, R. M. Gemmill, K. Ferguson, S. Kusy, J. Roche, E. Brambilla, C. Zeng, A. Baron, L. Bemis, P. Erickson, et al. WNT7a induces E-cadherin in lung cancer cells PNAS, September 2, 2003; 100(18): 10429 - 10434. [Abstract] [Full Text] [PDF]

				C. Poleri, J. L. Morero, B. Nieva, M. F. Vazquez, C. Rodriguez, E. de Titto, and M. Rosenberg Risk of Recurrence in Patients With Surgically Resected Stage I Non-small Cell Lung Carcinoma: Histopathologic and Immunohistochemical Analysis Chest, June 1, 2003; 123(6): 1858 - 1867. [Abstract] [Full Text] [PDF]

				R. M. Bremnes, R. Veve, E. Gabrielson, F. R. Hirsch, A. Baron, L. Bemis, R. M. Gemmill, H. A. Drabkin, and W. A. Franklin High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2002; 20(10): 2417 - 2428. [Abstract] [Full Text] [PDF]

				B. Halmos, C. S. Huettner, O. Kocher, K. Ferenczi, D. D. Karp, and D. G. Tenen Down-Regulation and Antiproliferative Role of C/EBP{alpha} in Lung Cancer Cancer Res., January 1, 2002; 62(2): 528 - 534. [Abstract] [Full Text] [PDF]

				P. G. Corn, E. I. Heath, R. Heitmiller, F. Fogt, A. A. Forastiere, J. G. Herman, and T.-T. Wu Frequent Hypermethylation of the 5' CpG Island of E-Cadherin in Esophageal Adenocarcinoma Clin. Cancer Res., September 1, 2001; 7(9): 2765 - 2769. [Abstract] [Full Text] [PDF]

				Y. Zhong, Y. Delgado, J. Gomez, S. W. Lee, and R. Perez-Soler Loss of H-Cadherin Protein Expression in Human Non-Small Cell Lung Cancer Is Associated with Tumorigenicity Clin. Cancer Res., June 1, 2001; 7(6): 1683 - 1687. [Abstract] [Full Text] [PDF]

				R T Pirinen, P Hirvikoski, R T Johansson, S Hollmen, and V-M Kosma Reduced expression of {{alpha}}-catenin, {beta}-catenin, and {{gamma}}-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer J. Clin. Pathol., May 1, 2001; 54(5): 391 - 395. [Abstract] [Full Text] [PDF]

				D. Liu, C.-l. Huang, K. Kameyama, E. Hayashi, A. Yamauchi, S. Kobayashi, and H. Yokomise E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer Ann. Thorac. Surg., March 1, 2001; 71(3): 949 - 954. [Abstract] [Full Text] [PDF]

				S. Kase, K. Sugio, K. Yamazaki, T. Okamoto, T. Yano, and K. Sugimachi Expression of E-cadherin and {beta}-Catenin in Human Non-Small Cell Lung Cancer and the Clinical Significance Clin. Cancer Res., December 1, 2000; 6(12): 4789 - 4796. [Abstract] [Full Text]

				P. G. Corn, B. D. Smith, E. S. Ruckdeschel, D. Douglas, S. B. Baylin, and J. G. Herman E-Cadherin Expression Is Silenced by 5' CpG Island Methylation in Acute Leukemia Clin. Cancer Res., November 1, 2000; 6(11): 4243 - 4248. [Abstract] [Full Text] [PDF]

				K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]